Menu
No results found.
Weekly Share Price & Valuation Overview
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. engages in production, purchase, and sale of pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. It also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, for the treatment of Secondary Hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- JPY 802.61B
- Enterprise Value Operating value: market cap + total debt − cash.
- JPY 807.27B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- JPY 496.73B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- JPY 341.44B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- JPY 86.19B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- JPY 1.06K
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 106.44
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 4.68%
- Shares Outstanding
- 469.77M
- Float Shares
- 389.31M
- Implied Shares Outstanding
- 469.77M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
17.25%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
17.35%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
68.74%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
8.64%
- Revenue Growth Year-over-year revenue growth.
-
8.40%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-28.80%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-28.70%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 2.18
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.18
- Total Cash Cash and equivalents.
- JPY 139.16B
- Total Debt Short + long-term interest-bearing debt.
- JPY 138.11B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- JPY -1.05B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 1.60
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- JPY 85.02B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
17.12%
- Cash Conversion (OpCF/EBITDA)
- 0.99
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.